The Breast Cancer Index (BCI) is one of the more accurate genomic tests available for predicting late breast cancer recurrence, the kind that happens five to ten years after diagnosis. In head-to-head comparison within the TransATAC study, BCI was the only test that significantly predicted late distant recurrence, outperforming both the 21-gene recurrence score (Oncotype DX) and IHC4 testing for that specific time window.
But “accurate” means different things depending on what you’re asking the test to do. BCI answers two distinct questions: How likely is your cancer to come back after year five? And would you personally benefit from extending hormone therapy beyond the standard five years? Its track record on both questions is strong, though not perfect.
What the Test Actually Measures
BCI analyzes the activity of two genes in your tumor tissue. One gene tends to be overactive in aggressive, treatment-resistant cancers. The other tends to be overactive in cancers with a favorable outcome. The ratio between these two genes reflects how well your tumor responds to estrogen signaling. When that signaling pathway is disrupted, whether through loss of hormone receptor function or interference from other growth signals, the ratio shifts in a direction associated with resistance to hormone therapy and higher recurrence risk.
This ratio is combined with a broader molecular profile to generate two outputs: a recurrence risk category (low or high) and a prediction of whether extended hormone therapy will benefit you specifically.
How Well It Predicts Late Recurrence
The strongest evidence for BCI’s accuracy comes from the TransATAC study, which directly compared it against other genomic tests for predicting distant recurrence between years five and ten. BCI produced a hazard ratio of 1.95 for late distant recurrence, meaning patients classified as higher risk were roughly twice as likely to have cancer return in that window. That result was statistically significant. By contrast, the 21-gene recurrence score (Oncotype DX) produced a hazard ratio of just 1.13 for the same late time period, which was not statistically significant. IHC4 testing also failed to reach significance.
This doesn’t mean Oncotype DX is a bad test. It performs well for predicting early recurrence in the first five years. The tests simply answer different questions at different time points, and the correlation between their scores is surprisingly low. One single-center analysis found only a weak positive correlation between Oncotype DX and BCI scores, and within specific score ranges, the correlation disappeared entirely. A low Oncotype score does not reliably predict what your BCI result will be.
Risk Categories and Survival Numbers
BCI places patients into low-risk and high-risk categories, and the gap between those groups is meaningful. In a study of tamoxifen-treated patients, those classified as BCI low risk had a 98% rate of staying free from distant recurrence in the first five years, compared to about 88% for high-risk patients. For late recurrence among patients who were already cancer-free at five years, the low-risk group maintained a 97% distant recurrence-free survival rate at ten years, while the high-risk group dropped to roughly 90%.
A separate multi-institutional study showed even wider separation. Low-risk patients had about 96% distant recurrence-free survival in the first five years versus 76% for high-risk patients. For late recurrence, the numbers were 97.5% versus 85%. These gaps are large enough to genuinely influence treatment decisions, though no test can tell any individual patient with certainty whether their cancer will return.
Predicting Who Benefits From Extended Therapy
This is where BCI offers something most other genomic tests cannot. After five years of hormone therapy, the standard decision point is whether to continue for another five years. Extended therapy reduces recurrence risk but comes with real side effects: joint pain, bone thinning, hot flashes, fatigue. BCI aims to identify which patients actually gain enough benefit to justify those tradeoffs.
In the MA.17 clinical trial, patients whose BCI classified them as likely to benefit from extended therapy saw their recurrence risk cut by more than half when they continued treatment, with an absolute risk reduction of nearly 10 percentage points. In a subgroup that had been on a specific treatment sequence, the absolute benefit reached 11.8 percentage points. Patients classified as unlikely to benefit showed no statistically significant improvement from continuing therapy. Their recurrence rates were essentially the same whether they stayed on treatment or stopped.
That’s a striking difference. It means roughly half of patients who might otherwise be told to continue hormone therapy could potentially stop at five years without meaningfully increasing their risk, while the other half stands to gain substantially from continuing.
Who the Test Is Designed For
BCI is validated for a specific patient profile. For recurrence risk assessment, you need to have hormone receptor-positive, HER2-negative invasive breast cancer with no lymph node involvement or only tiny deposits of cancer cells in the nodes (no larger than 2 mm). For the extended therapy prediction, the criteria are slightly broader, covering patients with up to three positive lymph nodes.
Medicare covers the test for postmenopausal women with early-stage disease (up to stage T3, with limited node involvement and no distant spread) when results will be used to guide chemotherapy or hormone therapy decisions. Private insurance coverage varies, and it’s worth confirming with your insurer before ordering.
What the Test Cannot Tell You
BCI is a probability tool, not a crystal ball. A low-risk classification means your statistical odds are favorable, but a small percentage of low-risk patients will still experience recurrence. Likewise, many high-risk patients will never see their cancer return. The test shifts the odds in a way that helps guide decisions, but it doesn’t eliminate uncertainty.
The test also wasn’t designed to predict recurrence in HER2-positive cancers, triple-negative breast cancers, or cancers that have already spread beyond the breast and nearby lymph nodes. Its accuracy figures apply only to the specific populations studied in clinical trials, predominantly postmenopausal women with hormone-sensitive, early-stage disease. If your cancer profile falls outside those parameters, BCI results may not apply to your situation in the same way.